Sunitinib Malate Capsules 25 mg
Nitnib 25 Capsule
Nitnib 25 Capsule is prescribed for the treatment of Gastrointestinal stromal tumour (GIST), Metastatic renal cell carcinoma (MRCC) and Pancreatic neuroendocrine tumours (pNET).
Nitnib 25 Capsule Composition :-
Nitnib 25 Capsule consists of : Sunitinib Malate 25 mg
Sunitinib Malate is a tyrosine kinase inhibitor.
Nitnib 25 Capsule Uses :-
Nitnib 25 Capsule is an anti-cancer medicine. Nitnib 25 Capsule is used for the treatment of :
• Gastrointestinal stromal tumor (GIST):
Imatinib is useful for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumors (GISTs) in adults after treatment failure.
• Metastatic Renal Cell Carcinoma (MRCC):
Useful for the treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults.
• Pancreatic neuroendocrine tumor (PNET):
Useful for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors (PNETs) with disease progression in adults.
Nitnib 25 Capsule Dosage :-
Nitnib 25 Capsule is a prescription medicine.
Take Nitnib 25 Capsule properly as your doctor tells you to take it.
Do take Nitnib 25 Capsule one time a day.
Do take Nitnib 25 Capsule with food or without food.
The recommended dosage of 50 mg once daily for GIST and MRCC for 4 consecutive weeks, followed by 2 weeks of discontinuation and a full cycle of 6 weeks throughout the duration.
The recommended dose for PNET is 37.5 mg taken once daily as prescribed.
If a dose is missed, the patient should not take an additional dose. From the next day onwards, the patient should take the usual prescribed dose.
Don't cut, crush, or chew the Nitnib 25 Capsule.
Nitnib 25 Capsule Side-effects :-
Common side effects of Nitnib 25 Capsule:
• Tiredness,
• Weakness,
• Diarrhea,
• Nausea,
• Loss of appetite,
• Abdominal pain,
• Taste changes
• Vomiting,
• Rash,
• Pain, swelling, or sores inside of mouth,
Nitnib 25 Capsule can make your skin appear pale. Your skin and hair color may become lighter. Nitnib 25 Capsule can also cause other skin problems such as: Dryness, cracking or thickening of the skin.
These are not all the possible side effects of Nitnib 25 Capsule. Consult your doctor and if you have any new or worsening side effects.
Precautions & Warnings :-
• Nitnib 25 Capsule can cause serious liver problems that can lead to death. Tell your doctor right away if you have signs of liver problems such as :
Yellow eyes or skin,
Dark urine,
Pain or discomfort in the right upper abdominal area.
You should have blood tests to check how your liver is working before and during treatment with Nitnib 25 Capsule. If you have liver problems, your doctor may temporarily stop, reduce the dose, or permanently stop treatment with Nitnib 25 Capsule.
• Some serious side effects of Nitnib 25 Capsule can occur, such as:
Heart problems.
Abnormal heart rhythm changes.
Causing irregular heartbeat.
Bleeding problems.
Having high blood pressure
Having severe stomach and intestinal problems.
Tumor lysis syndrome (TLS).
Abnormal changes in the brain.
Severe skin and mouth reactions.
Low blood sugar.
Wound healing problem.
Fetal damage.
• Before taking Nitnib 25 Capsule, tell your doctor about all of your medical conditions, such as:
Have a heart problem.
Have high blood pressure.
Seizures happen.
Thyroid problem.
Swelling inside the mouth Pain in the mouth, teeth, or jaw.
Have a history of low blood sugar or diabetes.
Have kidney function problems (besides cancer).
Have liver problem.
There is no bleeding problem.
Have had surgery recently or are planning to have surgery. Nitnib 25 Capsule should be stopped at least 3 weeks before surgery.
• Inform your doctor about all the medicines you take, some other medicine such as :
- Prescription and over-the-counter,
- Medicines,
- Vitamins,
- Herbal supplements,
Nitnib 25 Capsule Mfg By :-
Zydus Cadila
Nitnib 25 Capsule Price :-
MRP ₹ =
Nitnib 25 Capsule Storage :-
Nitnib 25 Capsule : store below 30°C
Classification :-
Drug Name : Sunitinib Malate,
Therapeutics Indiaction : Treatment of Gastrointestinal stromal tumour (GIST),
Metastatic renal cell carcinoma (MRCC),
Pancreatic neuroendocrine tumours (pNET).